Eric C Strain

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1668603/publications.pdf

Version: 2024-02-01

157 papers 8,300 citations

45 h-index 49909 87 g-index

162 all docs 162 docs citations

162 times ranked 6486 citing authors

#	Article	IF	CITATIONS
1	Wireless electroencephalography (EEG) to monitor sleep among patients being withdrawn from opioids: Evidence of feasibility and utility Experimental and Clinical Psychopharmacology, 2022, 30, 1016-1023.	1.8	7
2	The defining characteristic of substance use disorders. Drug and Alcohol Dependence, 2022, 230, 109207.	3.2	0
3	Fare well. Drug and Alcohol Dependence, 2022, 231, 109264.	3.2	O
4	Characterization of basal ganglia volume changes in the context of HIV and polysubstance use. Scientific Reports, 2022, 12, 4357.	3.3	4
5	A comparison of registered and published primary outcomes in clinical trials of opioid use disorder: ACTTION review and recommendations. Drug and Alcohol Dependence, 2022, 236, 109447.	3.2	O
6	P331. Meta-Analysis of Functional Imaging Studies of Acute Administration of Psychedelics. Biological Psychiatry, 2022, 91, S221.	1.3	0
7	Objective sleep outcomes in randomized-controlled trials in persons with substance use disorders: A systematic review. Drug and Alcohol Dependence, 2022, , 109509.	3.2	3
8	If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics. Journal of Pain, 2022, 23, 1666-1679.	1.4	8
9	Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Science Translational Medicine, 2022, 14, .	12.4	23
10	Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone. American Journal on Addictions, 2021, 30, 83-87.	1.4	56
11	News and social media coverage is associated with more downloads and citations of manuscripts that focus on substance use. Drug and Alcohol Dependence, 2021, 218, 108357.	3.2	3
12	Meaning and purpose in the context of opioid overdose deaths. Drug and Alcohol Dependence, 2021, 219, 108528.	3.2	4
13	Symptom severity and medication-assisted treatment for individuals with serious mental illness and a history of heroin use. Psychiatry Research, 2021, 296, 113671.	3.3	O
14	A preliminary examination of the multiple dimensions of opioid craving. Drug and Alcohol Dependence, 2021, 219, 108473.	3.2	10
15	Electronic health record adoption among US substance use disorder and other mental health treatment facilities. Drug and Alcohol Dependence, 2021, 220, 108515.	3.2	8
16	Hegemony, homogeneity, and DSM-5 SUD. Drug and Alcohol Dependence, 2021, 221, 108660.	3.2	7
17	Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder. Drug and Alcohol Dependence, 2021, 221, 108649.	3.2	3
18	Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations. Pain, 2021, 162, 2669-2681.	4.2	20

#	Article	IF	CITATIONS
19	Moving Beyond Medications That Act at the \hat{l} Receptor in the Treatment of Opioid Use Disorder. JAMA Psychiatry, 2021, 78, 701.	11.0	5
20	Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone. Drug and Alcohol Dependence, 2021, 226, 108869.	3.2	4
21	Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D. Journal of Addiction Medicine, 2021, 15, 325-333.	2.6	3
22	Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes. Addiction Biology, 2020, 25, e12680.	2.6	30
23	Experimental sleep disruption attenuates morphine analgesia: findings from a randomized trial and implications for the opioid abuse epidemic. Scientific Reports, 2020, 10, 20121.	3.3	19
24	Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome. Drug and Alcohol Dependence, 2020, 215, 108212.	3.2	8
25	A Randomized and Controlled Acceptability Trial of an Internet-based Therapy among Inpatients with Co-occurring Substance Use and Other Psychiatric Disorders. Journal of Dual Diagnosis, 2020, 16, 447-454.	1.2	5
26	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug and Alcohol Dependence, 2020, 212, 107993.	3.2	49
27	Integrated dual diagnosis treatment among United States mental health treatment facilities: 2010 to 2018. Drug and Alcohol Dependence, 2020, 213, 108074.	3.2	12
28	Protracted renal clearance of fentanyl in persons with opioid use disorder. Drug and Alcohol Dependence, 2020, 214, 108147.	3.2	49
29	Drug Legalization and Decriminalization Beliefs Among Substance-using and Nonusing Individuals. Journal of Addiction Medicine, 2020, 14, 56-62.	2.6	4
30	Relationship between cannabis use frequency and major depressive disorder in adolescents: Findings from the National Survey on Drug Use and Health 2012–2017. Drug and Alcohol Dependence, 2020, 208, 107867.	3.2	22
31	Gabapentin Enacarbil Extendedâ€Release for Alcohol Use Disorder: A Randomized, Doubleâ€Blind, Placeboâ€Controlled, Multisite Trial Assessing Efficacy and Safety. Alcoholism: Clinical and Experimental Research, 2019, 43, 158-169.	2.4	60
32	What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning?. Addiction, 2019, 114, 9-15.	3.3	56
33	The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal. Drug and Alcohol Dependence, 2019, 202, 111-114.	3.2	5
34	Time to Reconsider the Role of Craving in Opioid Use Disorder. JAMA Psychiatry, 2019, 76, 1113.	11.0	16
35	A Systematic Review of Laboratory Evidence for the Abuse Potential of Tramadol in Humans. Frontiers in Psychiatry, 2019, 10, 704.	2.6	34
36	Craving and opioid use disorder: A scoping review. Drug and Alcohol Dependence, 2019, 205, 107639.	3.2	31

#	Article	IF	Citations
37	Analgesic Effects of Hydromorphone <i>versus</i> Buprenorphine in Buprenorphine-maintained Individuals. Anesthesiology, 2019, 130, 131-141.	2.5	15
38	Medical Devices to Prevent Opioid Use Disorder. JAMA Psychiatry, 2019, 76, 351.	11.0	4
39	Trends in first-time treatment admissions for older adults with alcohol use disorder: Availability of medical and specialty clinical services in hospital, residential, and outpatient facilities. Drug and Alcohol Dependence, 2019, 205, 107694.	3.2	11
40	Differential adoption of opioid agonist treatments in detoxification and outpatient settings. Journal of Substance Abuse Treatment, 2019, 107, 24-28.	2.8	13
41	Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder. Drug and Alcohol Dependence, 2019, 194, 500-517.	3.2	39
42	Response to commentaries: The quest(ion) remains in the search for a meaningful reductionâ€based endâ€point. Addiction, 2019, 114, 21-23.	3.3	1
43	Tramadol Extended-Release and Opioid Withdrawal Management—Legal Implications—Reply. JAMA Psychiatry, 2018, 75, 215.	11.0	0
44	To take or not to take: the association between perceived addiction risk, expected analgesic response and likelihood of trying novel pain relievers in selfâ€identified chronic pain patients. Addiction, 2018, 113, 67-79.	3.3	11
45	Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients. Addictive Behaviors, 2018, 76, 8-14.	3.0	49
46	Sex and Age Differences in Risk Factors of Marijuana Involvement During Adolescence. Addictive Disorders and Their Treatment, 2018, 17, 29-39.	0.5	7
47	A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder. Drug and Alcohol Dependence, 2018, 193, 142-147.	3.2	80
48	Introduction to CPDD abstracts from the 2016 conference. Drug and Alcohol Dependence, 2017, 171, e1.	3.2	0
49	Efficacy of Tramadol Extended-Release for Opioid Withdrawal. JAMA Psychiatry, 2017, 74, 885.	11.0	42
50	Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence. Alcohol and Alcoholism, 2017, 52, 72-79.	1.6	7
51	A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence. Neuropsychopharmacology, 2017, 42, 1012-1023.	5.4	61
52	Prescriptions, Nonmedical Use, and Emergency Department Visits Involving Prescription Stimulants. Journal of Clinical Psychiatry, 2016, 77, e297-e304.	2.2	59
53	Temporal preference in individuals reporting chronic pain: discounting of delayed pain-related and monetary outcomes. Pain, 2016, 157, 1724-1732.	4.2	23
54	Initial feasibility and validity of a prospective memory training program in a substance use treatment population Experimental and Clinical Psychopharmacology, 2016, 24, 390-399.	1.8	5

#	Article	IF	Citations
55	Classifying substance use disorder treatment facilities with co-located mental health services: A latent class analysis approach. Drug and Alcohol Dependence, 2016, 163, 108-115.	3.2	15
56	Age and Gender Considerations for Technology-assisted Delivery of Therapy for Substance Use Disorder Treatment: A Patient Survey of Access to Electronic Devices. Addictive Disorders and Their Treatment, 2016, 15, 149-156.	0.5	4
57	A new Associate Editor for Drug and Alcohol Dependence: Dr. Adam Leventhal. Drug and Alcohol Dependence, 2016, 160, 1.	3.2	0
58	Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug and Alcohol Dependence, 2016, 158, 1-7.	3.2	49
59	Introduction. Drug and Alcohol Dependence, 2015, 156, e1.	3.2	0
60	Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence Psychology of Addictive Behaviors, 2015, 29, 237-246.	2.1	7
61	Recruitment Techniques for Alcohol Pharmacotherapy Clinical Trials. Addictive Disorders and Their Treatment, 2015, 14, 211-219.	0.5	4
62	Patterns of concurrent substance use among adolescent nonmedical ADHD stimulant users. Addictive Behaviors, 2015, 49, 1-6.	3.0	16
63	Effects of methadone plus alcohol on cognitive performance in methadone-maintained volunteers. American Journal of Drug and Alcohol Abuse, 2015, 41, 251-256.	2.1	10
64	Drug and Alcohol Dependence Fellowship. Drug and Alcohol Dependence, 2015, 153, 1.	3.2	0
65	Instruments to Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: An ACTTION Systematic Review. Journal of Pain, 2015, 16, 389-411.	1.4	26
66	A randomized controlled trial of the effects of working memory training in methadone maintenance patients. Drug and Alcohol Dependence, 2015, 156, 38-46.	3.2	79
67	Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients. Drug and Alcohol Dependence, 2015, 157, 143-149.	3.2	41
68	Sources of nonmedically used prescription stimulants: Differences in onset, recency and severity of misuse in a population-based study. Drug and Alcohol Dependence, 2014, 145, 106-112.	3.2	16
69	The Effect of Repeated Intramuscular Alfentanil Injections on Experimental Pain and Abuse Liability Indices in Healthy Males. Clinical Journal of Pain, 2014, 30, 36-45.	1.9	9
70	Employmentâ€based abstinence reinforcement promotes opiate and cocaine abstinence in outâ€ofâ€treatment injection drug users. Journal of Applied Behavior Analysis, 2014, 47, 681-693.	2.7	18
71	A Double Blind, within Subject Comparison of Spontaneous Opioid Withdrawal from Buprenorphine versus Morphine. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 217-226.	2.5	32
72	Behavioural health interventions in the Johns Hopkins Community Health Partnership: Integrated care as a component of health systems transformation. International Review of Psychiatry, 2014, 26, 648-656.	2.8	13

#	Article	IF	Citations
73	The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: A randomized controlled trial. Preventive Medicine, 2014, 68, 62-70.	3.4	22
74	Topiramate for cocaine dependence during methadone maintenance treatment: A randomized controlled trial. Drug and Alcohol Dependence, 2014, 140, 92-100.	3.2	43
75	Patterns of concurrent substance use among nonmedical ADHD stimulant users: Results from the National Survey on Drug Use and Health. Drug and Alcohol Dependence, 2014, 142, 86-90.	3.2	20
76	Methadone Safety: A Clinical Practice Guideline From the American Pain Society and College on Problems of Drug Dependence, in Collaboration With the Heart Rhythm Society. Journal of Pain, 2014, 15, 321-337.	1.4	203
77	Registered Reports: A new submission format at Drug and Alcohol Dependence. Drug and Alcohol Dependence, 2014, 137, 1-2.	3.2	8
78	Correlates of nonmedical use of stimulants and methamphetamine use in a national sample. Addictive Behaviors, 2014, 39, 829-836.	3.0	41
79	Cognitive performance in methadone maintenance patients: Effects of time relative to dosing and maintenance dose level Experimental and Clinical Psychopharmacology, 2014, 22, 248-256.	1.8	25
80	Opioid abusers' ability to differentiate an opioid from placebo in laboratory challenge testing. Drug and Alcohol Dependence, 2013, 132, 369-372.	3.2	5
81	Service Use and Barriers to Mental Health Care Among Adults With Major Depression and Comorbid Substance Dependence. Psychiatric Services, 2013, 64, 863-870.	2.0	101
82	Gender Differences in Substance Abuse Treatment and Barriers to Care Among Persons With Substance Use Disorders With and Without Comorbid Major Depression. Journal of Addiction Medicine, 2013, 7, 325-334.	2.6	94
83	A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence. Journal of Addiction Medicine, 2013, 7, 277-286.	2.6	220
84	Pretreatment Alcohol Drinking Goals are Associated with Treatment Outcomes. Alcoholism: Clinical and Experimental Research, 2013, 37, 1745-1752.	2.4	68
85	A Doubleâ€Blind, Placeboâ€Controlled Trial Assessing the Efficacy of Levetiracetam Extendedâ€Release in Very Heavy Drinking Alcoholâ€Dependent Patients. Alcoholism: Clinical and Experimental Research, 2012, 36, 1421-1430.	2.4	41
86	Comparison of cognitive performance in methadone maintenance patients with and without current cocaine dependence. Drug and Alcohol Dependence, 2012, 124, 167-171.	3.2	10
87	An fMRI Investigation of Cerebellar Function During Verbal Working Memory in Methadone Maintenance Patients. Cerebellum, 2012, 11, 300-310.	2.5	34
88	Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: Development and pilot test of a clinical protocol. Journal of Opioid Management, 2012, 8, 369-82.	0.5	48
89	Drug use and sport—A commentary on: Injury, pain and prescription opioid use among former National Football League football players by Cottler et al Drug and Alcohol Dependence, 2011, 116, 8-10.	3.2	2
90	The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A review. Drug and Alcohol Dependence, 2011, 119, 1-9.	3.2	53

#	Article	IF	Citations
91	A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. Journal of Substance Abuse Treatment, 2011, 40, 255-264.	2.8	40
92	Increased Blood Pressure After Abrupt Cessation of Daily Cannabis Use. Journal of Addiction Medicine, $2011, 5, 16-20$.	2.6	30
93	Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone Soluble-Films. Clinical Pharmacology and Therapeutics, 2011, 89, 443-449.	4.7	45
94	Response to "Commercial Factors Override Science in Combination Addiction Drug Trial― Clinical Pharmacology and Therapeutics, 2011, 90, 650-650.	4.7	0
95	Discriminative Stimulus Effects of Tramadol in Humans. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 255-262.	2.5	36
96	Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. Psychopharmacology, 2010, 210, 471-480.	3.1	27
97	Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers. Psychopharmacology, 2010, 211, 303-312.	3.1	21
98	Physical dependence potential of daily tramadol dosing in humans. Psychopharmacology, 2010, 211, 457-466.	3.1	59
99	The Relationship between Antidepressant Use and Smoking Cessation in Pregnant Women in Treatment for Substance Abuse. American Journal of Drug and Alcohol Abuse, 2010, 36, 46-51.	2.1	7
100	Effects of oral caffeine pretreatment on response to intravenous nicotine and cocaine Experimental and Clinical Psychopharmacology, 2010, 18, 305-315.	1.8	7
101	Cigarette smoking knowledge, attitudes, and practices of patients and staff at a perinatal substance abuse treatment center. Journal of Substance Abuse Treatment, 2010, 39, 298-305.	2.8	18
102	Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers. Drug and Alcohol Dependence, 2010, 111, 265-268.	3.2	31
103	Changes at Drug and Alcohol Dependence. Drug and Alcohol Dependence, 2010, 111, 3-3.	3.2	0
104	Caffeinated energy drinks—A growing problem. Drug and Alcohol Dependence, 2009, 99, 1-10.	3.2	791
105	Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug and Alcohol Dependence, 2009, 105, 154-159.	3.2	128
106	Screening for Mood Disorder in Pregnant Substance-dependent Patients. Addictive Disorders and Their Treatment, 2009, 8, 88-98.	0.5	3
107	Relationship between Cigarette Use and Mood/Anxiety Disorders among Pregnant Methadone-Maintained Patients. American Journal on Addictions, 2009, 18, 422-429.	1.4	22
108	Changing Profile of Abused Substances by Older Persons Entering Treatment. Journal of Nervous and Mental Disease, 2008, 196, 898-905.	1.0	74

#	Article	IF	Citations
109	Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug and Alcohol Dependence, 2007, 90, 261-269.	3.2	85
110	Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting. Journal of Substance Abuse Treatment, 2007, 33, 355-361.	2.8	2
111	Simultaneous determination of buprenorphine, norbuprenorphine and the enantiomers of methadone and its metabolite (EDDP) in human plasma by liquid chromatography/mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 850, 538-543.	2.3	36
112	Experimentally-Induced Spontaneous Opiate Withdrawal: Relationship to Cigarette Craving and Expired Air Carbon Monoxide. American Journal on Addictions, 2007, 16, 310-315.	1.4	2
113	Modest opioid withdrawal suppression efficacy of oral tramadol in humans. Psychopharmacology, 2007, 194, 381-393.	3.1	44
114	HIV risk behaviors during pharmacologic treatment for opioid dependence: A comparison of levomethadyl acetate hydrochloride, buprenorphine, and methadone. Journal of Substance Abuse Treatment, 2006, 31, 187-194.	2.8	30
115	Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans Experimental and Clinical Psychopharmacology, 2006, 14, 109-120.	1.8	18
116	Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. Psychopharmacology, 2006, 189, 297-306.	3.1	21
117	Decreased frontal white-matter volume in chronic substance abuse. International Journal of Neuropsychopharmacology, 2006, 9, 147.	2.1	94
118	Treatment of patients with substance use disorders, second edition. American Psychiatic Association. American Journal of Psychiatry, 2006, 163, 5-82.	7.2	62
119	Comparative Safety and Side Effect Profiles of Buprenorphine and Methadone in the Outpatient Treatment of Opioid Dependence. Addictive Disorders and Their Treatment, 2005, 4, 49-64.	0.5	14
120	Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence Experimental and Clinical Psychopharmacology, 2005, 13, 293-302.	1.8	63
121	Characteristics of older opioid maintenance patients. Journal of Substance Abuse Treatment, 2005, 28, 265-272.	2.8	86
122	Safety and Efficacy of L-tryptophan and Behavioral Incentives for Treatment of Cocaine Dependence: A Randomized Clinical Trial. American Journal on Addictions, 2004, 13, 421-437.	1.4	16
123	Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug and Alcohol Dependence, 2004, 74, 37-43.	3.2	68
124	A doseâ€"effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Drug and Alcohol Dependence, 2004, 74, 205-209.	3.2	38
125	Differences at Treatment Entry Between Opioid-Dependent and Cocaine-Dependent Males and Females. Addictive Disorders and Their Treatment, 2004, 3, 110-121.	0.5	3
126	Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction, 2003, 98, 427-439.	3.3	27

#	Article	IF	Citations
127	Single versus multiple drug focus in substance abuse clinical trials research: the devil is in the details. Drug and Alcohol Dependence, 2003, 70, 131-134.	3.2	4
128	Buprenorphine: how to use it right. Drug and Alcohol Dependence, 2003, 70, S59-S77.	3.2	214
129	Review: there is insufficient evidence for naltrexone maintenance treatment in opioid dependence. Evidence-Based Mental Health, 2003, 6, 57-57.	4.5	0
130	Assessment and Treatment of Comorbid Psychiatric Disorders in Opioid-Dependent Patients. Clinical Journal of Pain, 2002, 18, S14-S27.	1.9	105
131	Voucher-based reinforcement of opiate abstinence during methadone detoxification. Drug and Alcohol Dependence, 2002, 65, 179-189.	3.2	52
132	A Liquid Chromatographic-Electrospray Ionization-Tandem Mass Spectrometric Method for Determination of Buprenorphine, Its Metabolite, norBuprenorphine, and a Coformulant, Naloxone, That Is Suitable for in Vivo and in Vitro Metabolism Studies. Analytical Biochemistry, 2002, 306, 31-39.	2.4	124
133	Outpatient treatment entry and health care utilization after a combined medical/substance abuse intervention for hospitalized medical patients. Journal of General Internal Medicine, 2002, 17, 334-340.	2.6	9
134	Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology, 2002, 159, 161-166.	3.1	47
135	Outpatient Treatment Entry and Health Care Utilization After a Combined Medical/Substance Abuse Intervention for Hospitalized Medical Patients. Journal of General Internal Medicine, 2002, 17, 334-340.	2.6	24
136	Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology, 2001, 154, 230-242.	3.1	150
137	Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology, 2001, 157, 151-162.	3.1	221
138	Gradual Dose Taper Following Chronic Buprenorphine. American Journal on Addictions, 2001, 10, 111-121.	1.4	18
139	A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence. New England Journal of Medicine, 2000, 343, 1290-1297.	27.0	596
140	Moderate- vs High-Dose Methadone in the Treatment of Opioid Dependence. JAMA - Journal of the American Medical Association, 1999, 281, 1000.	7.4	378
141	Dose-Related Efficacy of Levomethadyl Acetate for Treatment of Opioid Dependence. Survey of Anesthesiology, 1998, 42, 98.	0.1	0
142	Site of Opioid Action in the Human Brain: Mu and Kappa Agonists' Subjective and Cerebral Blood Flow Effects. American Journal of Psychiatry, 1998, 155, 470-473.	7.2	137
143	Useful Predictors of Outcome in Methadone-Treated Patients. Journal of Maintenance in the Addictions, 1998, 1, 15-28.	0.1	15
144	Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug and Alcohol Dependence, 1997, 45, 81-91.	3.2	41

#	Article	IF	CITATIONS
145	Opioid antagonist effects of dezocine in opioid-dependent humans*. Clinical Pharmacology and Therapeutics, 1996, 60, 206-217.	4.7	17
146	Buprenorphine Versus Methadone in the Treatment of Opioid Dependence. Journal of Clinical Psychopharmacology, 1996, 16, 58-67.	1.4	115
147	A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence, 1995, 40, 17-25.	3.2	179
148	Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug and Alcohol Dependence, 1995, 40, 27-35.	3.2	89
149	Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology, 1994, 116, 401-406.	3.1	110
150	Outcome after methadone treatment: influence of prior treatment factors and current treatment status. Drug and Alcohol Dependence, 1994, 35, 223-230.	3.2	21
151	The Effects of Cocaine in Buprenorphine-Maintained Outpatient Volunteers:Results from Clinical Experience and Laboratory Challenges. American Journal on Addictions, 1994, 3, 129-143.	1.4	6
152	Methadone dose and treatment outcome. Drug and Alcohol Dependence, 1993, 33, 105-117.	3.2	106
153	Dose-Response Effects of Methadone in the Treatment of Opioid Dependence. Annals of Internal Medicine, 1993, 119, 23.	3.9	198
154	Withdrawal Syndrome after the Double-Blind Cessation of Caffeine Consumption. New England Journal of Medicine, 1992, 327, 1109-1114.	27.0	388
155	Clustering of multiple substance use and psychiatric diagnoses in opiate addicts. Drug and Alcohol Dependence, 1991, 27, 127-134.	3.2	56
156	Intravenous drug abusers with antisocial personality disorder: increased HIV risk behavior. Drug and Alcohol Dependence, 1990, 26, 39-44.	3.2	88
157	Modulation of cellular immunity in medical students. Journal of Behavioral Medicine, 1986, 9, 5-21.	2.1	363